A quiet shift has been taking place somewhere between the pharmacy counter and the wellness aisle. Individuals who cycled through SSRIs for years, adjusting dosages, putting up with weight gain, and overcoming the emotional flatness that many describe as feeling like life wrapped in cling film, have begun looking elsewhere. Some of them have discovered something that would have been limited to quiet conversations and festival grounds only a short time ago. They claim to be taking very small doses of LSD or psilocybin—not enough to cause hallucinations or ruin an afternoon, but enough to feel a change.
For those who are still catching up, microdosing entails taking about a tenth of the usual recreational dosage of a psychedelic drug. Over the course of several weeks, take 10 to 20 micrograms of LSD or 0.2 to 0.5 grams of dried psilocybin mushrooms two to four times a week. A trip is not the objective. It’s something more subdued, such as a reported alleviation of depression, a relaxation of the inflexible thought patterns that make anxiety seem unavoidable, and a feeling of cognitive flexibility that some users characterize as the difference between being stuck and being able to move again. Decades ago, Albert Hofmann, the chemist who synthesized LSD for the first time in 1938 and unintentionally discovered its effects, proposed that very small doses might be effective as an antidepressant. The rest of the world took some time to catch up.
| Topic | Microdosing as an Alternative to Traditional Antidepressants |
|---|---|
| Substances Involved | Psilocybin (magic mushrooms), LSD (lysergic acid diethylamide) |
| Typical Microdose | 10–20 mcg LSD / 0.2–0.5g dried psilocybin mushrooms |
| Dosing Frequency | 2–4 times per week, typically over several weeks |
| Key Institutions Researching | UCSF, UCLA, Imperial College London, Johns Hopkins University |
| Legal Status | Illegal in most countries; psilocybin rescheduled in Australia (2023) |
| Key 2026 Finding | Psychedelic-assisted therapy no more effective than open-label antidepressants (JAMA Psychiatry) |
| Reference Website | PubMed Central — Therapeutic Potential of Microdosing Psychedelics |
Anecdotal evidence has been accumulating for years, coming from observational surveys, online communities, and an increasing number of people who are fed up with the side effects of traditional treatment. Sexual dysfunction, emotional numbness, and weight gain are serious side effects for long-term antidepressant users. Many stop because of them. Therefore, even though the evidence for microdosing is still incredibly shaky, its appeal is understandable. Users frequently report feeling happier, being more focused, and having more engaged relationships. Some say they felt like themselves for the first time in years. These reports are worthy of serious consideration. They should also be examined.
As of early 2026, the scientific picture is far less neat than the testimonies. Researchers from UCSF, UCLA, and Imperial College London conducted a groundbreaking study that was published in JAMA Psychiatry in March 2026 in an attempt to address one of the main issues with psychedelic research: almost all participants in psychedelic trials are aware of whether they received the drug or a placebo because the drug exhibits noticeable effects even at higher doses. To get around this, the researchers compared open-label antidepressant trials, in which participants were also aware of what they were taking, with psychedelic-assisted therapy trials rather than placebos. The reasoning was clear. The outcome was sobering. On a 52-point scale, the difference in depression scores between the two methods was less than one point, making it clinically undetectable and statistically meaningless. The study’s clinical data scientist, Balázs Szigeti, acknowledged that he had anticipated psychedelics to win. They didn’t.
It’s important to consider the true implications of that, as it does not imply that psychedelic therapy or microdosing are ineffective. Both groups made significant progress. In both situations, depression scores decreased by about 12 points, indicating a genuine and substantial improvement in people’s lives. The narrative that psychedelics are a breakthrough, something wholly distinct from and better than what we already have, is what the study challenges. According to Sam Moreton of the University of Wollongong, the hype has continuously outpaced the evidence. Theoretically, there are compelling reasons to continue researching these compounds. The majority of current trials have seriously flawed methodology. It is not the same as having evidence that they are more effective.
The majority of the research focuses on full psychedelic doses given in therapeutic settings rather than the sub-perceptual amounts that people are actually using at home, which complicates the microdosing discussion. Only fourteen experimental studies that satisfied the criteria for investigating low-dose psychedelics were found in a review published in the journal Frontiers in Psychiatry; the majority of these studies were carried out on small groups of healthy volunteers rather than individuals with clinical depression. The results were genuinely intriguing: low doses of psilocybin and LSD seemed to result in modest gains in emotional processing, convergent thinking, and cognitive flexibility. Additionally, they occasionally caused a cyclical pattern of depressive and euphoric moods as well as elevated anxiety. In both directions, the image is not clear.
Researchers seem to be pursuing a moving target. The cultural discourse has advanced by the time a rigorous clinical trial is planned, financed, and finished. Millions of people are currently making private decisions about their mental health, ordering drugs through unofficial channels, modifying dosages in response to Reddit discussions, and keeping their results private. Although this isn’t specific to microdosing—people have always experimented with their own neurochemistry—the gap between public practice and scientific knowledge feels particularly large here, and closing it is made more difficult by the legal status of these substances in the majority of countries.
It’s difficult to ignore how the excitement surrounding microdosing is reminiscent of earlier periods in the history of psychiatry when a novel strategy was hailed as the solution to the problems that the earlier strategy was unable to resolve. The description of SSRIs used to be nearly identical: they were a more targeted, gentler, and cleaner alternative to the blunt pharmacology of earlier antidepressants. Many people were assisted by them. Additionally, it took years for their limitations to become fully apparent. As the microdosing discussion progresses, one is tempted to wonder if the pattern is recurring or if the mechanisms are truly different enough to be significant this time.
To be honest, no one knows yet. The placebo problem in psychedelic science is still genuinely unsolved, the trials are small, and the research is still in its infancy. What is evident is that depression is not adequately treated, that a significant portion of patients who take current medications experience side effects, and that there is genuine desperation behind the search for alternatives. In the future, microdosing might prove to be a valuable treatment tool. It might end up being a sophisticated placebo with a loyal following. As of right now, it is in the awkward middle of being too common to ignore, too promising to be taken seriously, and not sufficiently proven to be prescribed.